Market Overview

J&J's Janssen-Cilag's ZYTIGA Receives Positive EU Recommendation

Related JNJ
Earnings Season Is The Right Prescription For Health Care ETFs
3 Companies That Should Benefit From The New Initiative In Africa
Johnson & Johnson CEO: No Plans to Leave U.S. (Fox Business)

J&J's (NYSE: JNJ) Janssen-Cilag International NV (Janssen) announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of the oral, once-daily medication ZYTIGA® (abiraterone acetate) for use in combination with prednisone or prednisolone in the treatment of metastatic castration-resistant prostate cancer (mCRPC), in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated.1 If endorsed by the European Commission, the recommendation would expand the indication for ZYTIGA®, which is currently approved for use in combination with prednisone/prednisolone to treat men with mCRPC whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

Posted-In: News FDA

 

Related Articles (JNJ)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters